Viking Therapeutics - VKTX Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VKTX shares.
View VKTX analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 12 month price objectives for Viking Therapeutics' shares. Their VKTX share price forecasts range from $15.00 to $35.00. On average, they expect the company's stock price to reach $25.89 in the next year. This suggests a possible upside of 57.9% from the stock's current price.
View analysts price targets for VKTX or view top-rated stocks among Wall Street analysts.

Viking Therapeutics' stock was trading at $9.40 at the beginning of the year. Since then, VKTX stock has increased by 74.5% and is now trading at $16.40.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our VKTX earnings forecast.

Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its quarterly earnings data on Wednesday, February, 8th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.03.

ETFs with the largest weight of Viking Therapeutics (NASDAQ:VKTX) stock in their portfolio include SPDR S&P Biotech ETF (XBI), Invesco DWA SmallCap Momentum ETF (DWAS), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC) and

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Viking Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Boxer Capital LLC (1.96%), Two Sigma Investments LP (1.65%), Point72 Asset Management L.P. (1.44%), Renaissance Technologies LLC (1.24%), Dimensional Fund Advisors LP (1.11%) and Geode Capital Management LLC (0.85%). Insiders that own company stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends.

Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VKTX stock can currently be purchased for approximately $16.40.

Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $1.29 billion. The biotechnology company earns $-68,870,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at sdiaz@vidasp.com.